AD 337

Drug Profile

AD 337

Alternative Names: AD-337

Latest Information Update: 29 Jul 2015

Price : $50

At a glance

  • Originator Sosei R&D
  • Class Non-opioid analgesics
  • Mechanism of Action Adrenergic receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fibromyalgia

Most Recent Events

  • 18 Sep 2007 Results from a phase II clinical trial in patients with Fibromyalgia added to the adverse events and Rheumatic Disease therapeutic trials sections
  • 17 Oct 2006 Phase-II clinical trials in Fibromyalgia in Australia (PO)
  • 17 Oct 2006 Phase-II clinical trials in Fibromyalgia in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top